Table of Content

1. US Prostate Cancer Drug Market Overview


2. Approved Prostate Cancer Drugs Insight by Class
2.1 Chemotherapeutic Drugs
2.2 Hormonal Therapy
2.3 Immunotherapy
2.3.1 Cancer Vaccines
2.3.2 Immune Checkpoint Inhibitors
2.4 PARP Inhibitors


3. Novel Emerging Therapies in Prostate Cancer
3.1 Bi-Specific T-Cell Engagers (BiTE)
3.2 Small Molecule Prostate Cancer Drugs
3.3 Radioligand Therapy
3.4 Antibody Drug Conjugates


4. US Prostate Cancer Drugs: Generic & Biosimilar Landscape
4.1 Current Scenario & Price Differential
4.2 Reimbursement Scenario


5. Anti-Androgen Drugs for Prostate Cancer – US Market Availability, Dosage, Patent & Price Insight
5.1 Apalutamide (Erleada)
5.2 Xtandi (Enzalutamide)
5.3 Darolutamide (Nubeqa)
5.4 Abiraterone (Zytiga)
5.5 Bicalutamide (Casodex)
5.6 Nilutamide (Nilandron)
5.7 Flutamide



6. PARP Inhibitors for Prostate Cancer – US Market Availability, Dosage, Patent & Price Insight
6.1 Rucaparib (Rubraca)
6.2 Olaparib (Lynparza)


7. Radioactive Pharmaceutical Agents for Prostate Cancer – US Market Availability, Dosage & Price Insight
7.1 Radium 223 Dichloride (Xofigo)
7.2 Fluciclovine 18F (Axumin)


8. Mitotic Inhibitors for Prostate Cancer - US Market Availability, Dosage, Price & Patent Insight
8.1 Cabazitaxel (Jevtana)
8.2 Docetaxel (Taxotere)


9. Immunotherapeutics for Prostate Cancer – US Market Availability, Dosage & Price Insight
9.1 Provenge (Sipuleucel – T)
9.2 Capromab Pendetide (ProstaScint)


10. Gonadotropin Releasing Hormones Drugs for Prostate Cancer - US Market Availability, Dosage & Price Insight
10.1 Triptorelin (Trelstar)
10.2 Leuprolide
10.3 Goserelin (Zoladex)
10.4 Histrelin Acetate Subcutaneous Implant (Supprelin LA/Vantas)
10.5 Degarelix (Firmagon/Gonax)


11. Estrogens for Prostate Cancer - US Market Availability, Dosage & Price Insight
11.1 Estradiol
11.2 Conjugated Estrogen


12. Other Prostate Cancer Targeting Therapeutics - US Market Availability, Dosage & Price Insight
12.1 Estramustine (Emcyt)
12.2 Mitoxantrone (Novantrone)
12.3 Cyclophosphamide
12.4 Capecitabine (Xeloda)
12.5 Zoledronic Acid (Zometa/Reclast)


13. US - Prostate Cancer Drug Clinical Trials Overview
13.1 By Biomarket
13.2 By Drug Class
13.3 By Formulation
13.4 By Organization
13.5 By Patient Segment
13.6 By Phase


14. US - Prostate Cancer Drugs Clinical Pipeline By Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-0
14.6 Phase-I
14.7 Phase-I/II
14.8 Phase-II
14.9 Phase-III
14.10 Preregistration
14.11 Registered


15. US - Marketed Prostate Cancer Drugs Clinical Insight



16. US Prostate Cancer Market Dynamics
16.1 Market Drivers
16.2 Market Challenges


17. US Prostate Cancer Market Future Prospects


18. Compititive Landscape
18.1 AbbVie
18.2 Accord Healthcare
18.3 Allergan
18.4 Amgen
18.5 Astellas Pharma
18.6 AstraZeneca plc
18.7 Bayer
18.8 Bristol Mayer Squibb
18.9 Clovis Oncology
18.10 Dendreon
18.11 Genentech
18.12 Jassen Pharmaceuticals
18.13 Merck
18.14 Mylan
18.15 Novartis AG
18.16 Pfizer
18.17 Roche
18.18 Sanofi
18.19 Sun Pharma
18.20 Teva Pharmaceuticals